Ehrlichia canis and Monocytic Ehrlichiosis in Dogs: Tick-Borne Pathogenesis, Thrombocytopenia, and Clinical Management

Introduction

Canine monocytic ehrlichiosis (CME) is a globally distributed, potentially fatal tick-borne disease caused by the obligate intracellular bacterium Ehrlichia canis (Rickettsiales: Anaplasmataceae) [1, 2]. The primary vector is Rhipicephalus sanguineus sensu lato (the brown dog tick), which facilitates transmission through salivary secretions during blood feeding [3, 58, 63]. E. canis infects circulating monocytes and macrophages, leading to a spectrum of clinical manifestations ranging from subclinical infection to severe pancytopenia and death [75, 80, 90]. Disease severity is influenced by host immune status, bacterial strain virulence, and the presence of coinfecting pathogens such as Anaplasma platys, Babesia vogeli, or Hepatozoon canis [4, 32, 56, 71, 99]. This article provides a detailed, evidence-based review of the pathogen biology, transmission dynamics, immunopathogenesis, diagnostic strategies, and clinical management of CME, with emphasis on the hallmark hematologic abnormality of thrombocytopenia.

Pathogen Biology and Genomic Diversity

E. canis is a small (0.5 to 1.5 µm), Gram-negative, pleomorphic coccus that replicates within membrane-bound vacuoles (morulae) in mononuclear phagocytes [80, 85]. The bacterium possesses a reduced genome that relies on host cell metabolic machinery, particularly for ATP and amino acid biosynthesis [5]. Key immunodominant proteins include the 30 kDa outer membrane proteins (p28/OMP-1 family) and the tandem repeat protein 36 (TRP36; also known as TRP19 or gp36) [28, 60, 77]. These surface antigens exhibit substantial genetic diversity across geographic regions, enabling strain differentiation and influencing serodiagnostic performance [68, 78, 84, 86, 88, 92]. The p28 gene cluster encodes multiple paralogous proteins that undergo antigenic variation, potentially facilitating immune evasion [38, 39, 77]. TRP36 genotyping has identified several genogroups with distinct repeat motifs, including the United States (US), Brazilian, Costa Rican, and Thai genogroups [68, 78, 84, 88]. This diversity complicates vaccine development and may affect cross-protection. Comparative genomic analyses of Australian and global isolates have confirmed a high degree of synteny, with strain-specific variations in immunogenic loci.

Transmission and Vector Biology

Transmission of E. canis occurs primarily through the bite of infected R. sanguineus ticks during feeding. Transstadial transmission has been documented, but transovarial transmission is not considered a major route in this tick species [3, 30, 58]. The average time from tick attachment to bacterial transmission in experimental models is approximately 3 to 6 hours, with the speed influenced by the tick life stage and previous feeding status. Once infected, the tick remains competent for life. E. canis has also been detected in other tick species, including Dermacentor marginatus in sylvatic environments, although their vector competence requires further investigation [3, 48].

Environmental and host factors strongly influence transmission risk. High seroprevalence rates (40% to 80%) have been reported in tropical and subtropical regions where R. sanguineus is endemic, including Brazil, India, Thailand, Peru, and parts of Africa [1, 6, 7, 8, 9, 40, 45, 47, 53, 67, 70, 89]. In temperate zones, such as southern Europe and Australia, prevalence is lower but increasing due to climate change and dog movement [10, 11, 44, 98]. Free-roaming and stray dogs have significantly higher infection rates compared to companion animals, reflecting greater tick exposure [12, 7]. Vertical transmission (transplacental) has been demonstrated in naturally infected female dogs, suggesting that in utero infection may contribute to neonatal disease. Iatrogenic transmission through blood transfusion is a recognized risk, necessitating screening of canine blood donors [34, 52].

Pathogenesis and Immunopathology

Following inoculation, E. canis disseminates via the lymphatics and bloodstream to target organs rich in mononuclear phagocytes: spleen, liver, lymph nodes, bone marrow, and lungs [80, 90]. The bacterium enters host monocytes via receptor-mediated endocytosis and inhibits phagolysosomal fusion, creating an intracytoplasmic vacuole permissive for replication [13, 85]. Bacterial replication results in host cell lysis, releasing progeny that infect additional monocytes and macrophages.

Mitochondrial Dysfunction and Apoptosis

Infection induces significant mitochondrial dysfunction in host cells, characterized by reduced oxidative phosphorylation, increased reactive oxygen species production, and disruption of mitochondrial membrane potential [5]. Simultaneously, E. canis triggers endoplasmic reticulum (ER) stress, activating the unfolded protein response and promoting apoptosis via caspase-3 and caspase-9 activation [13]. The balance between pro-apoptotic and anti-apoptotic signals determines the outcome for the infected cell and influences disease severity.

Thrombocytopenia: Mechanisms and Clinical Significance

Thrombocytopenia is the most consistent hematologic abnormality in CME, occurring in 70% to 90% of naturally infected dogs [14, 15, 70, 90]. Multiple mechanisms contribute:

1. Immune-mediated platelet destruction. Platelet surface-associated immunoglobulin (PSIg) levels are significantly elevated in E. canis-infected thrombocytopenic dogs compared to healthy controls [14]. These anti-platelet antibodies may be directed against platelet antigens or against E. canis antigens adsorbed onto the platelet surface.

2. Splenic sequestration. Splenomegaly, a common finding in acute and chronic CME, increases platelet pooling within splenic sinusoids.

3. Bone marrow suppression. In chronic and severe cases, bone marrow examination reveals megakaryocytic hypoplasia or dysplasia, indicating reduced platelet production.

4. Consumption and vasculitis. Platelet consumption at sites of vascular injury (e.g., central nervous system vasculitis) and disseminated intravascular coagulation (DIC) in end-stage disease further exacerbate thrombocytopenia.

Co-infection with A. platys, which targets platelets directly, can worsen thrombocytopenia [14, 32, 100]. A meta-analysis confirmed that thrombocytopenia is significantly associated with elevated liver enzymes (alanine aminotransferase, alkaline phosphatase), suggesting concurrent hepatic inflammation [15].

Acute Phase Response and Cytokine Dysregulation

Infection elicits a robust acute phase response, with elevated serum C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-alpha) levels proportional to disease severity. These inflammatory mediators contribute to fever, lethargy, and anorexia. Hyperglobulinemia (especially polyclonal gammopathy) develops in the subacute and chronic phases as a result of sustained B-cell stimulation by bacterial antigens [80, 90].

Clinical Phases

CME is classically described in three phases: acute, subclinical, and chronic [87, 90].

The acute phase is characterized by fever (39.5°C to 41°C), depression, reduced appetite, and palpable lymphadenopathy [75, 90]. Ocular manifestations (uveitis, retinal hemorrhages, retinal detachment) are common and can be used as diagnostic indicators [16, 38]. The subclinical phase may persist for years; dogs remain seropositive and can serve as reservoirs for ticks [29, 98]. Progression to the chronic phase is more likely in immunosuppressed or co-infected animals and carries a guarded prognosis [37, 56, 62, 65, 79].

Central nervous system involvement, although rare, can manifest as meningitis or meningoencephalitis due to vasculitis or the presence of morulae within cerebrospinal fluid neutrophils or monocytes [37, 79]. Cases of neurologic ehrlichiosis are diagnostically challenging and often require advanced imaging and PCR of CSF.

Diagnosis

A multimodal diagnostic approach is recommended, combining hematologic assessment, serology, molecular detection, and, where available, advanced imaging or cytology.

Hematology and Clinical Pathology

The complete blood count (CBC) typically reveals thrombocytopenia (platelet count <200,000/µL, often <50,000/µL) [14, 15, 93]. Anemia (non-regenerative initially, regenerative later) and leukocyte abnormalities (neutropenia followed by neutrophilia, lymphopenia, and monocytosis) are variable. Biochemical abnormalities include hyperproteinemia (due to hyperglobulinemia), elevated liver enzymes (ALT, ALP), and decreased albumin [15, 17]. Coagulation profiles may show prolonged bleeding times but normal prothrombin and partial thromboplastin times, unless DIC has developed.

Cytology

Microscopic examination of Giemsa- or Wright-stained blood smears, buffy coat preparations, or lymph node aspirates may reveal intracytoplasmic morulae within monocytes or, less commonly, neutrophils [82, 85, 99]. The sensitivity is low (10% to 30%) compared to PCR, but specificity is high. In cases of co-infection with H. canis, gamonts and morulae may be observed in the same monocyte.

Serology

Detection of anti-E. canis antibodies is performed using indirect immunofluorescence assay (IFA) or enzyme-linked immunosorbent assay (ELISA) [42, 50, 53]. IFA using whole organisms is considered the reference method, but commercial ELISA kits (targeting p30 or p28 antigens) are widely used in field settings [42, 50]. Seroconversion occurs 7 to 21 days post-infection, and antibodies persist for months or years, limiting the utility of serology for distinguishing active from past infection [42, 98].

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting the 16S rRNA gene, p28 gene, or TRP36 gene offers high sensitivity and specificity [18, 35, 60, 70, 77]. Nested PCR and duplex/hexaplex assays can detect multiple tick-borne pathogens simultaneously [18, 35, 50]. Quantitative real-time PCR (qPCR) allows estimation of bacterial load, which correlates with disease severity and response to therapy [29, 75]. Droplet digital PCR (ddPCR) provides absolute quantification and has been validated for blood and ocular specimens, offering high accuracy even in dogs with low bacteremia [16, 29]. Loop-mediated isothermal amplification (LAMP) assays, targeting the p30 gene, represent a promising point-of-care molecular tool, especially in resource-limited settings.

Novel diagnostic approaches include UV spectroscopy combined with machine learning, which has shown promise for rapid, low-cost screening [19]. Portable electronic olfactometers using volatile organic compound (VOC) patterns from skin or breath samples, coupled with machine learning algorithms, are under investigation as non-invasive screening tools. Peptide microarrays containing immunoreactive epitopes from E. canis and A. platys have been used for high-throughput serological profiling.

flowchart TD
 A["Clinical suspicion: fever, thrombocytopenia, tick exposure"] --> B{CBC with platelet count}
 B -->|Platelets <200k| C[Perform serology and/or PCR]
 B -->|Platelets >200k| D["Assess other causes; re-evaluate if symptoms persist"]
 C --> E[IFA/ELISA positive?]
 C --> F[PCR positive?]
 E -->|Yes| G["Confirm active vs past infection: PCR or ddPCR"]
 E -->|No| F
 F -->|Yes| H[Diagnose acute/subacute CME]
 F -->|No| I[Consider other vector-borne or immune-mediated disease]
 G --> J[ddPCR positive? High bacterial load?]
 J -->|Yes| K[Start doxycycline therapy]
 J -->|No| L["Repeat serology in 2-3 weeks; monitor clinical signs"]
 K --> M[Recheck CBC and PCR after 14-21 days]
 M -->|Clinical improvement, PCR negative| N[Complete 28-day course]
 M -->|No improvement or positive PCR| O["Extend therapy; rule out resistance or co-infection"]
 O --> P[Consider alternative diagnosis or referral]

Clinical Management

Antimicrobial Therapy

The cornerstone of treatment is doxycycline hyclate or monohydrate administered orally at 5 mg/kg twice daily or 10 mg/kg once daily for a minimum of 28 days [21, 87]. A randomized clinical trial comparing once-daily versus twice-daily dosing found no significant difference in clinical cure or hematologic recovery rates, suggesting that a simplified once-daily regimen is efficacious and may improve owner compliance [21]. For dogs unable to tolerate oral therapy, injectable doxycycline may be used.

Tetracycline antibiotics inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit; they are bacteriostatic but effective due to the slow replication rate of E. canis. In dogs with severe thrombocytopenia or hemorrhage, doxycycline is still indicated; however, transfusion of fresh whole blood or platelet-rich plasma may be necessary to control life-threatening bleeding.

Supportive Care

Supportive management includes fluid therapy (balanced crystalloids) for dehydrated or hypotensive dogs, antiemetics if gastrointestinal signs are present, and nutritional support (appetite stimulants or enteral feeding). Corticosteroids are generally contraindicated due to the risk of exacerbating immunosuppression; however, in cases of severe immune-mediated thrombocytopenia refractory to doxycycline, a short course of prednisone (0.5 to 1 mg/kg twice daily for 3 to 5 days) may be considered under careful monitoring [14].

Acaricide Prevention

Preventing tick exposure is critical in endemic areas. Topical or oral acaricides (e.g., isoxazoline compounds such as afoxolaner, fluralaner, or sarolaner) provide rapid tick kill and prevent transmission of E. canis [91, 98]. Integrated tick control in the environment (kennel hygiene, removal of leaf litter, and treating premises with acaricides) is also recommended.

Vaccination

No commercial vaccine is currently available for CME. Experimental vaccines using attenuated live E. canis strains or recombinant proteins (TRP19, TRP36) have shown partial protection in dogs, reducing clinical severity but not preventing infection [22, 23, 97, 102]. Targeted mutagenesis of a phage head-to-tail connector protein gene has produced a live attenuated candidate with reduced virulence, but further safety and efficacy studies are needed before field application [22].

Prognosis

With early diagnosis and appropriate doxycycline therapy, the prognosis for acute and subclinical CME is good. Clinical signs typically resolve within 24 to 72 hours of treatment initiation, and platelet counts normalize within 1 to 3 weeks [21, 87]. Chronic CME, particularly when pancytopenia and bone marrow hypoplasia are present, carries a guarded to poor prognosis despite therapy. Fatal outcomes are more common in dogs with concurrent infections (e.g., Babesia vogeli, Hepatozoon canis, Bartonella clarridgeiae) or secondary complications such as DIC, sepsis, or severe pulmonary hemorrhage [56, 62, 65, 76].

Conclusions

Ehrlichia canis remains a major cause of tick-borne morbidity in dogs worldwide, with thrombocytopenia as the hallmark laboratory abnormality arising from immune-mediated destruction, sequestration, and bone marrow suppression. Advances in molecular diagnostics, including ddPCR and multiplex PCR, have improved detection sensitivity and differentiation of co-infections. Doxycycline-based therapy is highly effective, but prevention through acaricide use and environmental tick management is essential for population-level control. Continued research into genetic diversity, vaccine development, and point-of-care diagnostics will further refine clinical management and reduce the global impact of CME.

References

[1] Montoya-Matute A, Checa R, Gómez-Velasco C, et al. Nationwide seroprevalence of canine vector-borne pathogens in dogs in Spain. Parasit Vectors. 2026. https://pubmed.ncbi.nlm.nih.gov/42289747/

[2] Ebani VV. Ehrlichia canis: Is It a Pathogen for Humans and Other Primates? Pathogens. 2026. https://pubmed.ncbi.nlm.nih.gov/41754488/

[3] Picazio G, Cardillo L, Pucciarelli A, et al. Detection of Ehrlichia canis in Rhipicephalus sanguineus and Dermacentor marginatus from sylvatic environments in Southern Italy. Vet Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41886246/

[4] Araújo BVS, Bezerra ILPD, Leite GL, et al. Epidemiological and clinicopathological factors associated with infection by multiple pathogens transmitted by Rhipicephalus sanguineus sensu lato in naturally infected dogs in the Semiarid area of Northeastern Brazil. Comp Immunol Microbiol Infect Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42127483/

[5] Tong X, Jiang J, Yang L, et al. Mitochondrial Dysfunction in Ehrlichia canis Infection. Transbound Emerg Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42200149/

[6] Shil S, Chini DS, Mukherjee A, et al. Molecular standardization and epidemiological mapping of canine haemoprotozoa in West Bengal, India. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/42276665/

[7] Kongtawee R, Junsiri W, Narapakdeesakul D, et al. High burden and spatial clustering of canine hemoparasitic infections in southern Thailand: A molecular survey of free-roaming dogs. One Health. 2026. https://pubmed.ncbi.nlm.nih.gov/41737196/

[8] Ramírez-Reyes RP, Quispe-Rodríguez LK, Macedo-Macedo R, et al. High seroprevalence, clinical predictors, and epidemiological risk factors of Ehrlichia canis infection in dogs on the Northern Coast of Perú: A large-scale cross-sectional study. Vet World. 2025. https://pubmed.ncbi.nlm.nih.gov/41716169/

[9] Linares DFB, Martins KR, Joanol Dallmann PR, et al. Molecular prevalence of Ehrlichia canis in dogs examined at the Hospital de Clínicas Veterinárias of Universidade Federal de Pelotas, Southern Rio Grande do Sul, Brazil. Parasite Epidemiol Control. 2026. https://pubmed.ncbi.nlm.nih.gov/41695717/

[10] Wang W, Davis S, Johnstone-Robertson S. Canine ehrlichiosis in Northern Australia: A sensitivity and elasticity analysis of R(0). Ticks Tick Borne Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42030626/

[11] Hughes R, Ciavarella AA, Courtman NF, et al. Two cases of Ehrlichia canis acquired locally in Victoria. Aust Vet J. 2026. https://pubmed.ncbi.nlm.nih.gov/41711344/

[12] Pham BX, Phoosangwalthong P, Inkaew T, et al. The Comparative Study for Detection of Canine Vector-Borne Pathogens Between Companion and Stray Dogs in Bangkok and Vicinities, Thailand. Pathogens. 2026. https://pubmed.ncbi.nlm.nih.gov/42198653/

[13] Yanar KE, Gür C, Kirman R, et al. Immune activation and endoplasmic reticulum stress-mediated apoptosis in dogs naturally infected with Ehrlichia canis. Vet Immunol Immunopathol. 2026. https://pubmed.ncbi.nlm.nih.gov/41894865/

[14] Boontuboon W, Sakcamduang W, Osathanon R, et al. Evaluation of platelet surface-associated immunoglobulin positivity and its association with hematologic findings and vector-borne pathogens in thrombocytopenic dogs. J Vet Intern Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41789552/

[15] Kumar A, Sharma A, Kumar V, et al. Association of thrombocytopenia and liver enzymes in canine monocytic ehrlichiosis: a meta-analysis. J Parasit Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41768922/

[16] Kanittakul K, Sumpavong P, Sritrakoon N, et al. Clinical evaluation of a validated droplet digital PCR assay for the detection of Ehrlichia canis in ocular and blood specimens from seroreactive dogs. Vet Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41932048/

[17] Martínez-Durán D, Mujika M, Morales M, et al. Vector-borne pathogens in Spanish greyhounds from Central Spain: Prevalence and hematobiochemical findings. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41741046/

[18] Pati M, Patra RC, Dehuri M, et al. Development of hexaplex PCR assay for the detection and characterization common tick-borne pathogens in dogs, and analysis of risk factors. Vet Anim Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42257235/

[19] Seidenfuss Antunes LB, França T, Sobota IP, et al. UV spectroscopy associated with machine learning as a complementary tool for the diagnosis of Ehrlichia canis in dogs. Photodiagnosis Photodyn Ther. 2026. https://pubmed.ncbi.nlm.nih.gov/42217715/

[21] Taechikantaphat M, Kongchareon A, Julapanthong P, et al. Comparative efficacy of once-daily versus twice-daily doxycycline regimens in dogs naturally infected with Ehrlichia canis: A randomized clinical trial. Vet Anim Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/42078964/

[22] Ferm DD, Nair A, Ferm JD, et al. Targeted mutagenesis in Ehrlichia canis deleting the phage head-to-tail connector protein gene and its assessment as a vaccine candidate preventing canine ehrlichiosis. Vaccine. 2026. https://pubmed.ncbi.nlm.nih.gov/41844092/

[23] Nambooppha B, Muenthaisong A, Koonyosying P, et al. Immunization with Recombinant TRP19 Reduces Clinical Severity of Experimental Ehrlichia canis Infection in Dogs. Biology (Basel). 2026. https://pubmed.ncbi.nlm.nih.gov/41823867/

[24] García Ríos IJM, Sebastian PS, Vaschalde PJ, et al. Circulation of Anaplasma platys, Babesia vogeli and Ehrlichia canis in dogs from eastern Salta Province, Argentina. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/42150808/

[25] Venugopal V, Deepa PM, Muhasin Asaf VN, et al. Molecular epidemiology and phylogenetics of canine haemoprotozoan and rickettsial infections in southern India. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41651622/

[26] Gurrola Ramírez A, Dzul Rosado KR, Castro Del Campo N, et al. Molecular detection and genetic analysis of Rickettsia, Ehrlichia, and Bartonella in ectoparasites from domestic dogs in Sinaloa, Mexico. Vet Parasitol Reg Stud Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/41651617/

[27] Kwarteng SA, Mensah JO, Obuam PK, et al. Occurrence of Tick-Borne Pathogens in Rhipicephalus sanguineus Sensu Lato From Domestic Dogs in Kumasi, Ghana. Vet Med Int. 2026. https://pubmed.ncbi.nlm.nih.gov/41614084/

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.